← All Pliant Therapeutics, INC filings

Pliant Therapeutics, INC Form 4 insider transactions

NASDAQ
PLRX
Pliant Therapeutics, INC
Form 4: Pliant Therapeutics Director Acquires 53,528 Stock Options
Director Steve E. Krognes acquired 53,528 stock options in Pliant Therapeutics on June 13, 2024, at an exercise price of $13.06.
NASDAQ
PLRX
Pliant Therapeutics, INC
Form 4: Pliant Therapeutics CFO Exercises Stock Options and Acquires Shares
Keith Lamont Cummings, CFO of Pliant Therapeutics, exercised stock options and acquired 21,000 shares of common stock at $2.08 per share on May 2, 2024.